Recombinant HGH (Somatropin): A Complete Research Guide

Recombinant human growth hormone — sold generically as somatropin — is one of the most extensively characterized peptide hormones in the endocrine literature. It is also one of the most frequently misunderstood in research-compound contexts, where dose units (IU versus mg), reconstitution practice, and timing conventions vary widely between protocols. This guide summarizes what is reasonably well established about recombinant somatropin: its structure, pharmacokinetics, typical research dose ranges, injection and storage practice, and the blood markers most commonly used to verify biological activity.

Structure and pharmacology

Endogenous human growth hormone is a 191-amino-acid, single-chain polypeptide of approximately 22 kDa, secreted in a pulsatile pattern by the somatotroph cells of the anterior pituitary. Recombinant somatropin produced via E. coli expression systems — the dominant manufacturing route since the mid-1980s — reproduces this 191-amino-acid sequence exactly, distinguishing it from the earlier 192-amino-acid somatrem (Protropin) analog that carried an extra N-terminal methionine. Research using modern recombinant products such as Novatrop HGH and Ansomone HGH therefore reflects the behavior of sequence-identical somatropin, not a structural variant.

Somatropin exerts its effects through two overlapping mechanisms. Direct binding to the growth hormone receptor (GHR) on peripheral tissues triggers JAK2/STAT5 signaling, driving lipolysis in adipocytes and stimulating hepatic gluconeogenesis. Indirect effects are mediated by insulin-like growth factor 1 (IGF-1), which is synthesized primarily in the liver in response to GHR activation and circulates bound to IGFBP-3. IGF-1 is the principal mediator of somatropin's anabolic and mitogenic effects on skeletal muscle, cartilage, and bone — a distinction that matters because IGF-1, not GH itself, is the marker most clinicians and researchers track.

The circulating half-life of injected recombinant somatropin is short — roughly 2 to 4 hours after subcutaneous administration — but the downstream IGF-1 elevation persists far longer, with serum IGF-1 remaining above baseline for 18 to 24 hours after a single subQ dose. This pharmacokinetic mismatch between parent compound and principal effector is the reason most research protocols focus on steady-state IGF-1 rather than peak GH levels.

IU-to-mg conversions and dose ranges

Recombinant somatropin is almost universally dosed in International Units (IU) in research-compound contexts, even though the underlying mass unit is milligrams. The WHO-accepted conversion is 1 mg somatropin = approximately 3 IU, which means a 10 mg vial contains roughly 30 IU, and a common 4 IU research dose corresponds to approximately 1.33 mg. Mislabeling — particularly vials marked only in mg on secondary packaging but in IU on the vial itself — is a recurring source of dose error, and verifying the IU marking on the vial is the first step in any reconstitution.

Published research and clinical protocols cluster into three broad ranges that appear repeatedly in the literature:

• Replacement / anti-aging range: 1–2 IU per day. This is near the physiologic replacement dose used in adult growth hormone deficiency (AGHD) trials (Rudman et al., 1990, and subsequent replicated protocols). It typically produces modest IGF-1 elevation without significant side effect burden.
• Recovery / recomposition range: 2–3 IU per day. Reported in research contexts for connective-tissue recovery and modest body-composition shifts. IGF-1 usually climbs into the upper-normal range.
• Performance / pharmacologic range: 4–8 IU per day. Associated in the literature with more pronounced lipolytic and anabolic effects but also with a sharply higher side effect profile, particularly water retention, carpal tunnel symptoms, and impaired glucose tolerance.

Doses above 8 IU per day appear in some older bodybuilding literature but are rarely represented in controlled studies, and the side effect burden at those doses — particularly insulin resistance — limits their research relevance. Dose-response for IGF-1 is not linear at the upper end; diminishing returns on IGF-1 elevation above approximately 6 IU have been reported in multiple pharmacokinetic studies.

Splitting the daily dose — for example, 2 IU in the morning and 2 IU in the afternoon on a 4 IU protocol — is a common practice intended to approximate the pulsatile endogenous pattern and reduce peak-related side effects, though head-to-head evidence that split dosing outperforms single daily injection on IGF-1 AUC is limited.

AM versus PM timing

Timing of somatropin administration is one of the more debated questions in the applied literature, and the evidence is genuinely mixed. Two competing arguments anchor the discussion.

The AM-dosing argument centers on preserving endogenous nocturnal GH pulses. Endogenous GH secretion peaks during slow-wave sleep in the first half of the night; exogenous somatropin administered in the evening raises circulating GH and IGF-1 at a time when the pituitary would otherwise be secreting its own pulse, and negative feedback may suppress that pulse. Morning injection, the argument goes, preserves the nocturnal pulse and simply adds daytime exposure.

The PM-dosing argument centers on growth and recovery processes that are most active overnight, and on the practical observation that daytime injection can blunt the lipolytic effect of endogenous fasted-morning GH secretion. Researchers working on body-composition endpoints sometimes prefer evening administration for this reason.

The honest summary is that neither position is well settled by controlled data in research-compound dose ranges. For IGF-1 elevation as an endpoint, timing appears to matter less than consistency; for endogenous pulse preservation, morning dosing has the stronger theoretical case.

Reconstitution and storage

Lyophilized somatropin is a fragile protein. Reconstitution errors — particularly the choice of diluent — are a common reason research batches underperform expected IGF-1 response.

The appropriate diluent is bacteriostatic water (BAC water), which contains 0.9% benzyl alcohol as a preservative. BAC water is preferred over plain sterile water for two reasons: first, the benzyl alcohol inhibits microbial growth in the multi-use vial across the reconstituted shelf life; second, and more importantly in practice, sterile water (unbuffered, preservative-free) has been reported to accelerate degradation of the somatropin protein in multi-use vials, likely through a combination of pH drift and the absence of the stabilizing preservative environment. Single-use reconstitution with sterile water immediately before injection is acceptable, but is rarely practical in research contexts where a vial is used over 1–2 weeks.

Reconstitution technique matters. BAC water should be added slowly down the side of the vial, not injected directly onto the lyophilized cake, and the vial should be gently swirled — never shaken — until the powder dissolves. Foaming indicates protein denaturation and should be avoided.

Post-reconstitution stability is finite. Reconstituted somatropin held at 2–8°C retains full potency for approximately 14 to 21 days depending on the specific formulation; some manufacturer data extends to 28 days. Outside this window, gradual loss of bioactivity has been reported even when the solution remains visibly clear. Room-temperature exposure beyond a few hours meaningfully accelerates degradation, and freezing reconstituted solution is not recommended.

Injection technique

Recombinant somatropin is administered subcutaneously in virtually all research and clinical contexts. Intramuscular injection is occasionally described in older protocols but offers no pharmacokinetic advantage and carries more local irritation risk.

The preferred site is the abdominal subcutaneous tissue, specifically the lateral regions at least 5 cm from the umbilicus. Abdominal SubQ injection provides a large, well-vascularized depot with reasonably consistent absorption kinetics. Thigh and deltoid sites are acceptable alternatives and produce similar absorption profiles in published comparisons, though abdominal injection has been associated with slightly faster onset of peak serum levels. Rotation between sites reduces the risk of localized lipoatrophy or lipohypertrophy, both of which have been reported with long-term repeated injection at a single site.

Insulin syringes — typically 29–31G, 8 mm — are standard. The small volumes involved (often 10–20 units on a U-100 insulin syringe, depending on reconstitution ratio) do not require larger gauges. Injection at a 45- to 90-degree angle into a pinched fold of subcutaneous tissue is the conventional technique.

IGF-1 monitoring and side effects

The single most informative blood marker in a somatropin research protocol is serum IGF-1, typically measured as total IGF-1 in ng/mL. Baseline IGF-1 should be drawn before the first dose; follow-up measurement at 4 to 6 weeks into a stable protocol gives a reasonable readout of biological response. Age- and sex-adjusted reference ranges apply — a 35-year-old male baseline of 180 ng/mL is not interpretable the same way as a 60-year-old's 180 ng/mL.

IGFBP-3 is sometimes measured alongside IGF-1 to compute the IGF-1/IGFBP-3 molar ratio, which some researchers argue is a more stable marker of GH axis status than total IGF-1 alone. Fasting glucose, HbA1c, and fasting insulin round out the minimum panel, because glucose dysregulation is the most clinically significant of somatropin's dose-dependent side effects.

The side effect profile is well characterized and strongly dose-dependent:

• Water retention and peripheral edema. Most commonly reported at initiation and at doses above 3 IU. Usually attenuates over 2–4 weeks as fluid balance re-equilibrates.
• Carpal tunnel syndrome and paresthesias. Related to fluid retention in tight fascial compartments. More common in women and at higher doses; typically reversible on dose reduction.
• Arthralgia and joint stiffness. Often reported in the first weeks of a protocol; mechanism is thought to involve both fluid shifts and direct connective-tissue effects.
• Insulin resistance and impaired fasting glucose. The most clinically significant dose-limiting side effect, typically emerging at doses above 4 IU and becoming consistent above 6 IU. Reversible on discontinuation in most published protocols, but long-term high-dose exposure has been associated with persistent glucose dysregulation.
• Benign intracranial hypertension. Rare, reported primarily in pediatric AGHD populations, but documented.

Research protocols routinely cap exposure at 4–6 months continuous use with bloodwork checkpoints, rather than running open-ended administration. The rationale is primarily to monitor glucose handling and IGF-1 drift over time, both of which can shift in the second and third months of a protocol in ways that are not predictable from the first-month bloodwork.

Open questions

Several aspects of recombinant somatropin research remain genuinely unsettled. Optimal dose-splitting frequency — once daily, twice daily, or the 5-on-2-off pattern sometimes reported in older literature — has not been rigorously compared on IGF-1 AUC endpoints in research-compound dose ranges. The interaction between somatropin and concurrent compounds commonly studied alongside it — including the GHRH analogs and GHRP peptides — is described mechanistically but rarely quantified in controlled protocols. And the long-term safety of sustained IGF-1 elevation into the upper-normal range, as distinct from the supraphysiologic range, is an area where longitudinal data in healthy-adult research populations is thin.

For researchers working with recombinant somatropin — whether Novatrop HGH at 100, 150, or 200 IU presentations, or Ansomone HGH — the practical implication is that IGF-1 bloodwork, careful reconstitution with BAC water, and conservative dose titration do more to generate interpretable data than any specific timing or injection-site convention.